CN109790158A - 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途 - Google Patents

作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途 Download PDF

Info

Publication number
CN109790158A
CN109790158A CN201780044794.3A CN201780044794A CN109790158A CN 109790158 A CN109790158 A CN 109790158A CN 201780044794 A CN201780044794 A CN 201780044794A CN 109790158 A CN109790158 A CN 109790158A
Authority
CN
China
Prior art keywords
pyrrolo
pyrimidine
pyridin
amino
trifluoroethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780044794.3A
Other languages
English (en)
Other versions
CN109790158B (zh
Inventor
张文燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Longbotai Pharmaceutical Co Ltd
Original Assignee
Tianjin Longbogene Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Longbogene Pharmaceutical Co ltd filed Critical Tianjin Longbogene Pharmaceutical Co ltd
Publication of CN109790158A publication Critical patent/CN109790158A/zh
Application granted granted Critical
Publication of CN109790158B publication Critical patent/CN109790158B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

公开了一类作为JAK抑制剂杂环衍生物，及该化合物的盐类，(II)、(III)、R的定义详见说明书。此外，还公开了以该化合物、及其盐类为活性成分的药物，及其在制备治疗免疫系统疾病、类风湿关节炎、肿瘤等与JAK相关靶点疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (8)

  1. PCT国内申请，权利要求书已公开。
CN201780044794.3A 2016-07-26 2017-07-25 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途 Active CN109790158B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610590791 2016-07-26
CN2016105907917 2016-07-26
CN201710037675 2017-01-19
CN2017100376757 2017-01-19
PCT/CN2017/094253 WO2018019222A1 (zh) 2016-07-26 2017-07-25 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途

Publications (2)

Publication Number Publication Date
CN109790158A true CN109790158A (zh) 2019-05-21
CN109790158B CN109790158B (zh) 2022-06-24

Family

ID=61015611

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780044794.3A Active CN109790158B (zh) 2016-07-26 2017-07-25 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
CN201780044487.5A Active CN109843883B (zh) 2016-07-26 2017-07-25 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780044487.5A Active CN109843883B (zh) 2016-07-26 2017-07-25 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途

Country Status (6)

Country Link
US (2) US11414413B2 (zh)
EP (2) EP3492468B1 (zh)
JP (2) JP6978097B2 (zh)
KR (2) KR102598246B1 (zh)
CN (2) CN109790158B (zh)
WO (2) WO2018019222A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790158B (zh) 2016-07-26 2022-06-24 苏州隆博泰药业有限公司 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
EP3842431B1 (en) * 2018-08-23 2023-12-27 Zhuhai United Laboratories Co., Ltd. [1,2,4]triazolo[1,5-a]pyridine compound as jak inhibitor and application thereof
CN111620873B (zh) * 2019-02-28 2021-12-28 沈阳药科大学 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途
CN110028509B (zh) * 2019-05-27 2020-10-09 上海勋和医药科技有限公司 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
AU2020428591B2 (en) * 2020-02-13 2024-05-23 Zhuhai United Laboratories Co., Ltd. Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
CA3166743A1 (en) * 2020-02-21 2021-08-26 Weiwei Mao Crystalline forms of jak inhibitor and uses thereof
EP4285899A1 (en) * 2021-01-29 2023-12-06 Zhuhai United Laboratories Co., Ltd. Oral preparation containing jak inhibitor or salt thereof or crystal form thereof, preparation method therefor, and application thereof
WO2023239727A1 (en) * 2022-06-06 2023-12-14 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Lats inhibitors and uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228161A (zh) * 2005-05-20 2008-07-23 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的吡咯并吡啶类
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
CN101801971A (zh) * 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
CN102026999A (zh) * 2008-03-11 2011-04-20 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
CN103254190A (zh) * 2005-12-13 2013-08-21 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
WO2013173506A2 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
CN103764654A (zh) * 2011-08-01 2014-04-30 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CN106905322A (zh) * 2016-01-26 2017-06-30 杭州华东医药集团新药研究院有限公司 吡咯嘧啶五元氮杂环衍生物及其应用
CN107531695A (zh) * 2015-04-29 2018-01-02 无锡福祈制药有限公司 Jak抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453548C2 (ru) 2006-01-17 2012-06-20 Вертекс Фармасьютикалз Инкорпорейтед Азаиндолы, полезные в качестве ингибиторов янус-киназ
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
CA2648250A1 (en) 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CN109790158B (zh) 2016-07-26 2022-06-24 苏州隆博泰药业有限公司 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228161A (zh) * 2005-05-20 2008-07-23 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的吡咯并吡啶类
CN101801971A (zh) * 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
CN103254190A (zh) * 2005-12-13 2013-08-21 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
CN102026999A (zh) * 2008-03-11 2011-04-20 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
CN103764654A (zh) * 2011-08-01 2014-04-30 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
WO2013173506A2 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
CN107531695A (zh) * 2015-04-29 2018-01-02 无锡福祈制药有限公司 Jak抑制剂
CN106905322A (zh) * 2016-01-26 2017-06-30 杭州华东医药集团新药研究院有限公司 吡咯嘧啶五元氮杂环衍生物及其应用

Also Published As

Publication number Publication date
JP6978097B2 (ja) 2021-12-08
EP3492468A1 (en) 2019-06-05
EP3492469B1 (en) 2021-12-01
US11279699B2 (en) 2022-03-22
WO2018019222A1 (zh) 2018-02-01
US20190270740A1 (en) 2019-09-05
US11414413B2 (en) 2022-08-16
CN109843883A (zh) 2019-06-04
KR102492378B1 (ko) 2023-01-27
JP2019532913A (ja) 2019-11-14
CN109843883B (zh) 2022-01-14
KR20190034234A (ko) 2019-04-01
EP3492468B1 (en) 2022-02-23
EP3492469A1 (en) 2019-06-05
KR102598246B1 (ko) 2023-11-02
EP3492469A4 (en) 2019-10-09
JP6978098B2 (ja) 2021-12-08
EP3492468A4 (en) 2020-03-04
KR20190035755A (ko) 2019-04-03
WO2018019223A1 (zh) 2018-02-01
JP2019532914A (ja) 2019-11-14
CN109790158B (zh) 2022-06-24
US20200190080A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
CN109790158A (zh) 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
JP6456900B2 (ja) キナーゼ調節のための化合物と方法、及びそのための適応
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
AU2006226322B2 (en) Heterobicylic inhibitors of HCV
KR102470598B1 (ko) 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물
US9346809B2 (en) Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors
EA039357B1 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
KR102686957B1 (ko) 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물
TWI707855B (zh) 咪唑并嗒類化合物及其用途
WO2020055636A1 (en) Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
AU2015317937B2 (en) Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound
JP2022502484A (ja) キナーゼ阻害活性を有する芳香族複素環式化合物
CN112341431A (zh) 作为fgfr4抑制剂的杂环化合物
JP2024522210A (ja) 複素環系ｊａｋ阻害剤
TW202246259A (zh) 吡唑醯胺衍生物
CN111072655B (zh) 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
EA039344B1 (ru) Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
JP2010037268A (ja) 新規縮合ピリミジン誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190805

Address after: Room 745, 2 Blocks, Fenghua Commercial Plaza, Mudu Town, Wuzhong District, Suzhou City, Jiangsu Province

Applicant after: Suzhou Longbotai Pharmaceutical Co., Ltd.

Address before: Room 219, second floor, A1 floor, Tianda Science Park, 80 Fourth Avenue, Jinshi Development Zone, 300457

Applicant before: TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD.

TA01 Transfer of patent application right
CB02 Change of applicant information

Address after: 215126 Room 623, 6 storeys, 3 Block 118 Shengpu Road, Suzhou Industrial Park, Jiangsu Province

Applicant after: Suzhou Longbotai Pharmaceutical Co., Ltd.

Address before: Room 745, 2 Blocks, Fenghua Commercial Plaza, Mudu Town, Wuzhong District, Suzhou City, Jiangsu Province

Applicant before: Suzhou Longbotai Pharmaceutical Co., Ltd.

CB02 Change of applicant information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004455

Country of ref document: HK

CB03 Change of inventor or designer information

Inventor after: Yang Hengying

Inventor after: Kuang Sheng

Inventor after: Li Shiwei

Inventor after: Wu Kuiwang

Inventor after: Li Shuxin

Inventor before: Zhang Wenyan

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: AM

Ref document number: 40004455

Country of ref document: HK

Free format text: CORRECTED DATA OF SECTION 72, 27.07.2022

Effective date: 20220727